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Abstract
Background: To detect the expression of multidrug resistance molecules P-glycoprotein (P-gp),
Lung resistnce protein (LRP) and Multidrug resistance-associated protein (MRP) and analyze the
relationship between them and the clinico-pathological features.
Methods: The expressions of P-gp, LRP and MRP in formalin-fixed paraffin-embedded tissue
sections from 59 gastric cancer patients were determined by a labbelled Streptavidin-Peroxidase
(SP) immunohistochemical technique, and the results were analyzed in correlation with
clinicopathological data. None of these patients received chemotherapy prior to surgery.
Results: The positive rates of P-gp, LRP, MRP were 86.4%, 84.7% and 27.1%, respectively. The
difference between the positive rate of P-gp and MRP was significant statistically, as well as the
difference between the expression of MRP and LRP. No significant difference was observed
between P-gp and LRP, but the positively correlation between the expression of P-gp and LRP had
been found. No significant correlation between the expression of P-gp, LRP, MRP and the grade of
differentiation were observed. The expression of P-gp was correlated with clinical stages positively
(r = 0.742), but the difference with the expression of P-gp in different stages was not significant.
Conclusion: The expressions of P-gp, LRP and MRP in patients with gastric cancer without prior
chemotherapy are high, indicating that innate drug resistance may exist in gastric cancer.
Background
Gastric cancer (GC) is one of the most common malig-
nancies worldwide. Despite noticeable advancements in
the prevention, diagnosis and treatment, GC still accounts
for over 10% of global cancer mortality, and remains the
second most frequent cause of cancer death after lung can-
cer [1,2], while in Asia, it is the top killing cancer [3].
Among the estimated 934,000 GC new cases and 700,000
GC deaths in 2002, China alone accounts for almost 42%
of the global total, with age-standardized incidence rates
of 41.4/100,000 for males and 19.2/100,000 for females
[2]. A recent national survey in China shows that GC is the
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No 3 cancer killer after lung cancer and liver cancer, with
24.71/100,000 death rate [4].
Current major treatment modalities for GC include sur-
gery and chemotherapy/radiotherapy. Curative gastrec-
tomy with proper loco-regional lymph node dissection is
the treatment of choice for resectable GC [5]. The effects
of chemotherapy for GC are limited because multidrug
resistance (MDR) problem in the primary tumor usually
leads to treatment failure. There are quite a number of dif-
ferent mechanisms accounting for drug resistance, and
MDR protein family plays an essential role. MDR refers to
subsequent and cross-over resistance to drug of different
categories, after exposure of tumor to a chemotherapeutic
agent [6]. Currently, the over expressions of P-glycopro-
tein (P-gp), Multidrug resistance-associated protein
(MRP) and Lung resistnce protein (LRP) are most exten-
sively studied in MDR. Using immunohistochemical tech-
nique, this study was to determine the protein expressions
of P-gp, LRP and MRP in GC tissues from patients without
chemotherapy, and explored their expressions with clin-
ico-pathological factors.
Materials and methods
Patients and tissue samples
GC specimens from 59 patients without prior chemother-
apy were collected from HeJi Hospital affiliated to
Changzhi Medical College from January 2001 to Decem-
ber 2003. All tumors were fixed with formalin and embed-
ded with paraffin. There were 46 (78.0%) males and 13
(22.0%) females with the median age of 55 years (range:
32~75 years). Pathological diagnoses were poorly differ-
entiated adenocarcinoma in 18 cases (30.5%), moder-
ately differentiated adenocarcinoma in 23 cases (39.0%),
well differentiated adenocarcinoma in 8 cases (13.6%),
mucous adenocarcinoma in 6 cases (10.2%) and
unknown pathological type in 4 cases (6.8%).
Regents
The reagents used in this study were rabbit anti-MRP1 (bs-
0657R, 1:300 dilution), rabbit anti-pGP/MDR1/gp170
(bs-0563R, 1:300 dilution), rabbit anti-LRP (bs-0661R,
1:300 dilution) and Biotin conguated Goat Anti-rabbit
IgG, all obtained from Beijing Biosynthesis Biotechnology
Corporation (Beijing, China). Bovine serum albumin
(BSA, 2%), IHC Biotin Block Kit, Streptavidin-Peroxidase
and diaminobenzidine (DAB) were from Fujian Maixin
Biotechnology Corporation (Fuzhou, China).
Immunohistochemistry
Immunolocalization of MDR markers were performed
according to the streptavidin-biotin peroxidase complex
method by Truong [7]. Tissue slides were first deparaffin-
ized in xylol, ethanol, and water, and then endogenous
peroxidase activity was blocked by immersion in 3%
H2O2 in methanol for 10 min to prevent any nonspecific
binding. For staining, the slides were pretreated in 0.01 M
citrate buffer (pH 6.0) and heated in a microwave oven
(98°C) for 10 min. After blocking with BSA, the slides
were incubated with the primary antibodies for P-gp, LRP
and MRP for 90 min at 37°C, then incubated with the sec-
ondary antibody (biotin-labeled anti-rabbit IgG goat anti-
body) for 15 min at 37°C, and finally incubated with
peroxidase-labeled streptavidin for 15 min. The reaction
products were visualized with diaminobenzidine.
Positive cells were stained brownish granules. Ten high
power fields in each slide were selected randomly and
observed double blind by two investigators. The staining
score of each section were calculated by staining intensity
and positive rate of cancer cells. For the quantification of
staining intensity, the score of no staining, weak staining,
moderate staining and strong staining was 0, 1, 2 and 3
respectively. Positive rate score of cancer cells was: 0-10%
was recorded as 0; 10-30% was recorded as 1; 30-50% was
recorded as 2; 50-75% were recorded as 3; >75% were
recorded as 4. The sum of scores was computed as the
score of staining intensity added the score of the positive
rate of cancer cells. Then it was graded according the sum
of scores: 0-1 (-); 2-3 (+); 4-5 (++); 6-7 (+++).
Statistical Analysis
All the experiment data is integrated into a comprehensive
data set. Numerical data were recorded directly and meas-
urement data were described as median and range. We
analyzed categorical variables using the Pearson Chis-
square test and Gamma test. Statistical analysis was per-
formed on SPSS software version 13.0 (SPSS Inc. Chicago,
IL), and P < 0.05 was considered as statistically significant.
Results
Location and distribution of P-gp, LRP and MRP
There was a clear background without nonspecific stain-
ing in negative control slides (Fig 1A). The three proteins
were stained brownish granules, with P-gp mainly located
on the membrane and cytoplasm (Fig 1B), LRP on peri-
nuclear cytoplasm (Fig 1C), and MRP on the membrane
and cytoplasm (Fig 1D). The characteristic distribution
pattern of three proteins was scattered expression in
tumor tissue, although small areas of diffused expression
were also observed.
The expression of P-gp, LRP and MRP
In the 59 cases, the positive rate of P-gp (86.4%) was sig-
nificantly higher than MRP (27.1%) (P = 0.000). No sig-
nificant difference between the expression of P-gp
(86.4%) and LRP (84.7%) were observed (P = 1.000), but
we found the positive correlation between them (r =Journal of Experimental & Clinical Cancer Research 2009, 28:144 http://www.jeccr.com/content/28/1/144
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0.803). The positive rate of LRP (84.7%) was significantly
higher than MRP (27.1%) (P = 0.000) (Table 1).
The relationship between the pathological types and the 
expression of P-gp, LRP and MRP
There were no statistically significant differences in the
expressions of P-gp, LRP and LRP among different patho-
logical types (P values are 0.561, 0.661 and 0.297, respec-
tively). No significant difference between the expression
of P-gp and LRP in poorly differentiated adenocarcinoma
were observed (P = 0.716), but we showed a low positive
correlation between them (r = 0.376) (Table 2).
The relationship between clinico-pathological stages and 
the expression of P-gp, MRP and LRP
P-gp was positively correlated with clinical stages (r =
0.742). There was a trend towards more advanced clinical
stages with higher P-gp positive rate, although the differ-
ences among different clinical stages were not statistically
significant (P = 0.304). The differences of LRP and MRP
among different clinical stages were not statistically signif-
icant (P = 0.087 and 0.380, respectively) (Table 3).
Discussion
Chemotherapy is an important treatment option in the
multi-disciplinary treatment strategy against GC. It has
been established that postoperative chemotherapy could
help reduce the recurrence and improve the progression-
free survival in resectable GC [8-10] and even in meta-
static GC [11]. Most patients, however, will ultimately
experience relapse and treatment failure usually within 2-
3 years after surgery. A major cause for such recurrence is
the chemoresistance in GC, which results from several
molecular mechanisms. Among these, drug efflux trans-
porters are the most intensively studied molecular fami-
lies, including ATP-binding-cassette (ABC transporter)
[12], which uses ATP to pump drugs out of the target cell
and reduce the intracellular drug concentrations leading
to drug resistance. Two members of the ABC transporter
superfamily including P-gp and MRP play a major role in
resistance [13]. Lung resistance protein (LRP) is a member
of the vault proteins involved in MDR. LRP has been
shown to shuttle anthracyclines out of the nucleus [14].
The expression of P-gp, MRP and LRP are positively corre-
lated with the level of drug resistance. The assessment of
MDR proteins over-expression is useful in determining
the most appropriate chemotherapy regimen for GC.
However, the positive rates of P-gp, MRP and LRP
reported in the literature are variable. Alexander et al. [15]
found by immunohistochemistry that the positive rates of
MRP, LRP and P-gp were 55%, 10% and 0%, respectively.
Fan et al. [16] found by reverse transcription polymerase
chain reaction (RT-PCR) in 50 GC patients that the mRNA
expressions of MRP, LRP, and MDR1 were 12.0%, 10.0%
and 10.0%, respectively. More recent studies [17-19]
using immunohistochemistry found that the positive
rates of MRP and LRP ranged from 39.4% to 88.9%. The
positive rates of these three MDR markers in our 59
The expression of P-gp (B), LRP (C) and MRP (D) in gastric  cancer tissues Figure 1
The expression of P-gp (B), LRP (C) and MRP (D) in 
gastric cancer tissues. A. Negative control; B. IHC detec-
tion of P-gp; C. IHC detection of LRP; D. MRP detection of 
MRP. All with hematoxylin background staining (× 400).
Table 1: The Expression of P-gp, MRP and LRP in 59 cases with gastric cancer
expression**
MDR proteins* ---
n (%)
+
n (%)
++
n (%)
+++
n (%)
Positive numbers***
n (%)
P-gp 8 (13.6) 21 (35.6) 19 (32.2) 11 (18.6) 51 (86.4)
LRP 9 (15.3) 12 (20.3) 24 (40.7) 14 (23.7) 50 (84.7)
MRP 43 (72.9) 12 (20.3) 4 (6.8) 0 (0.0) 16 (27.1)
* r = 0.803, The expression of P-gp is correlated stong positively with LRP.
** P = 0.298, P-gp vs LRP.
*** P = 0.000, P-gp vs MRP; P = 0.000, LRP vs MRP; P = 1.000, P-gp vs LRP.
Pearson Chis-square test; Gamma testJournal of Experimental & Clinical Cancer Research 2009, 28:144 http://www.jeccr.com/content/28/1/144
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patients are higher compared with those results, probably
due to improved detection technology.
Our study found no significant differences among the
expressions of P-gp, MRP and LRP in GC of different path-
ological types, in agreement with findings by Shi et al
[20], who found that the positive rates of P-gp and LRP
were 49.2% and 58%, respectively, and such expression
was closely related to clinicopathological staging but not
related to tumor differentiation. In our study, MRP and
LRP expression was not related to tumor invasion depth
or lymphatic metastasis. Based on these findings, we pro-
pose that innate resistance may exist in those 59 GC
patients even without prior chemotherapy.
P-gp confers resistance to cytotoxicity by chemotherapy
drugs, cytokine TNF-alpha, and ultraviolet light [21]. Fag-
gad et al. [22] found that MRP1 expression was as an inde-
pendent negative prognostic factor for overall survival in
ovarian cancer. As the patients in our group had mixed
postoperative treatment, it is impossible to correlate these
findings with clinical outcomes. This is the limitation of
the current study, and future work should be done to elab-
orate on this issue.
The expression of P-gp, MRP and LRP confers different
drug resistance profiles [23], including P-gp conferring
resistance to doxorubicin, vincristine, vinblastine, actino-
mycin-D and paclitaxel, MRP conferring resistance to
etoposide and epirubicin, and LRP conferring resistance
to carboplatin and Melphalan. Our study found these
molecules are interrelated, and P-gp is correlated with LRP
(r = 0.803), especially for moderately differentiated aden-
ocarcinoma (r = 0.915). The finding suggests that both
two resistance mechanisms exist in most patients.
As the resistance mechanisms of P-gp, MRP and LRP are
clarified, suggestions are proposed if we can block all the
ABC transporters at once [24]? Recent studies revealed
some new methods to overcome MDR, such as specific
PI3K inhibitors to reduce P-gp [25,26]. Du [27] showed
that RP L6 could regulate MDR in GC cells by suppressing
drug-induced apoptosis. Robey [28] reported an initial
phase I studies of CBT-1, an orally-administered, bisben-
zylisoquinoline plant alkyloid as P-gp inhibitor. CBT-1 at
Table 2: The expression of P-gp, MRP and LRP in patients with gastric cancer of different pathological types
Positive rates of MDR proteinsb
Pathological typesa Numbers P-gp*
n (%)
LRP**
n(%)
MRP***
n(%)
Poorly differentiated adenocarcinoma# 18 16 (88.9) 17 (94.4) 6 (33.3)
Moderately differentiated adenocarcinoma## 23 18 (78.3) 18 (78.3) 3 (13.0)
Well differentiated adenocarcinoma ### 8 7 (87.5) 7 (87.5) 4 (50.0)
Mucous adenocarcinoma 6 6 (100) 5 (83.3) 2 (33.3)
Others c 4 4 (100) 3 (75.0) 1 (25.0)
a Comparison between the expression of P-gp and LRP in the same pathological types:
#:P = 0.716; r = 0.376
##:P = 0.915; r = 0.913
###:P = 0.686; r = 0.414
bComparison among different pathological types for the same protein:
*P = 0.561
**P = 0.297
***P = 0.661
cOthers included well differentiated squamous carcinoma one case, unknown pathological types 3 cases.
Pearson Chis-square test and Gamma test
Table 3: The relationship between clinico-pathological stages of 
gastric cancer and P-gp, MRP and LRP
Positive rates of MDR proteins
Stages Numbers
n(%)
P-gp*
n(%)
MRP
n(%)
LRP
n(%)
TNM stages
T2 13 (22.0) 12 (92.3) 6 (46.2) 10 (76.9)
T3 44 (74.6) 37 (84.1) 10 (22.7) 39 (88.6)
T4 2 (3.4) 2 (100) 0 (0.0) 1 (50.0)
N0 24 (40.7) 21 (87.5) 10 (41.7) 21 (87.5)
N1 18 (30.5) 14 (77.8) 2 (11.1) 15 (83.3)
N2 15 (25.4) 14 (93.3) 3 (20.0) 12 (80.0)
N3 2 (3.4) 2 (100) 1 (50.0) 2 (100.0)
M0 57 (96.6) 49 (86.0) 16 (28.1) 49 (86.0)
M1 2 (3.4) 2 (100.0) 0 (0.0) 1 (50.0)
Clinical stages
IB 10 (16.9) 10 (100) 6 (60.0) 9 (90.0)
II 13 (22.0) 10 (76.9) 4 (30.8) 11 (84.6)
IIIA 18 (30.5) 14 (77.8) 2 (11.1) 16 (88.9)
IIIB 14 (23.7) 13 (92.9) 3 (21.4) 12 (85.7)
IV 4 (6.8) 4 (100) 1 (25.0) 2 (50.0)
* The positive rate of P-gp is correlated positively with clinical stages 
(r = 0.742).Journal of Experimental & Clinical Cancer Research 2009, 28:144 http://www.jeccr.com/content/28/1/144
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1 μM completely reversed P-gp-mediated resistance to vin-
blastine, paclitaxel and depsipeptide.
Although the value of systemic chemotherapy for GC is
controversial, several studies have demonstrated that GC
could benefited for chemotherapy [29], although MDR
remains a major challenge to effective chemotherapy [30].
Combined determination of P-gp, MRP and LRP may help
tailor the chemotherapy regimes and predict the out-
comes of treatment.
Conclusion
There are high percentages of innate expressions of P-gp,
LRP and MRP in GC without prior chemotherapy, which
may contribute to the poor response to chemotherapy of
GC.
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